NEW YORK, NY / ACCESSWIRE / December 21, 2019 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

LogMeIn, Inc. (NASDAQ:LOGM)

The investigation concerns whether LogMeIn and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the sale of LogMeIn to affiliates of Francisco Partners and Evergreen Coast Capital Corporation for $86.05 per share. If you are a LogMeIn shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/logmein-inc-logm-stock-merger-francisco-partners-evergreen/.

Telaria, Inc. (NYSE:TLRA)

The investigation concerns whether Telaria and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the merger between Telaria and The Rubicon Project, Inc. If you are a Telaria shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/telaria-inc-tlra-stock-merger-rubicon-project/.

TiVo Corporation (NASDAQ:TIVO)

The investigation concerns whether TiVo and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the merger between TiVo and Xperi Corporation. If you are a TiVo shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/tivo-corporation-stock-merger-xperi/.

On behalf of shareholders of these companies, Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060

sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

SOURCE: Halper Sadeh LLP

ReleaseID: 571041

NEW YORK / ACCESSWIRE / December 21, 2019 / Pomerantz LLP announce that a class action lawsuit has been filed against Canopy Growth Corporation ("Canopy" or the "Company") (NYSE: CGC) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-11341, is on behalf of a class consisting of investors who purchased or otherwise acquired Canopy securities between September 8, 2017 and November 13, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Canopy securities during the class period, you have until January 20, 2020 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here for information about joining the class action]

Canopy operates through two segments-Cannabis Operations and Canopy Rivers. The Company's products include dried flowers, oils and concentrates, softgel capsules, and hemps. It offers its products under the Tweed, Spectrum, DNA Genetics, CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Maitri brands. The Company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Canopy had exaggerated and/or overestimated the potential market for its products in Canadian retail stores; (ii) as a result, Canopy had failed to properly account for inventory and demand for its products, leading to inventory write-offs and restructuring charges; (iii) all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On November 14, 2019, Canopy announced its financial results for the second quarter of fiscal year 2020, which ended on September 30, 2019 (the "2Q20 Press Release"). Among other results, the 2Q20 Press Release reported revenue that fell below the lowest analyst estimate and an EBITDA loss of C$155.7 million, which one analyst described as "astounding." The 2Q20 Press Release further advised investors that it was unlikely to meet its previous revenue guidance of C$250 million by the fiscal fourth quarter. As explained by Canopy's Chief Executive Officer ("CEO"), Mark Zekulin ("Zekulin"), "provinces have reduced purchases to lower inventory levels, retail store openings have fallen short of expectations, and Cannabis 2.0 products are yet to come to market." The 2Q20 Press Release further advised that, "[a]s part of a management-initiated portfolio review, the Company has taken a restructuring charge of $32.7 million for returns, return provisions, and pricing allowances primarily related to its softgel & oil portfolio"; "recorded an inventory charge of $15.9 million to align the portfolio with the new strategy"; and that "[t]he Q2 2020 gross margin impact of the portfolio restructuring costs is $40.4 million."

On this news, Canopy's stock price fell $2.66 per share, or 14.38%, to close at $15.84 per share on November 14, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 570975

SHENZHEN,CHINA/ ACCESSWIRE / December 21, 2019 / In recent years, Germany Jassen Group has made many breakthroughs in the research and development of hyaluronic acid. The light luxury skin care brand of the group, OJESH, has the production technology of hyaluronic acid with the minimum molecular value. Moreover, a number of technologies used during the production have obtained German patent certifications. In particular, the biodegradable extraction micromolecule technology and HTN patented extraction technology are highly acclaimed internationally.

Recently, hyaluronic acid skin care has been loved by the many women. It is the light luxury skin care brand, OJESH,  owned by Jassen Group from Germany, that managed to keep the molecules of its hyaluronic acid as small as possible. OJESH hyaluronic acid's molecular weight is between 3000-5000 Dalton – it's almost the world's smallest hyaluronic acid molecule. The smaller the molecular weight, the easier it is for the hyaluronic acid to be absorbed by the skin, the better the hydrating and moisturizing effect are. At present, the reference value of small molecule hyaluronic acid is decreasing under the endeavor of science and technology.

Reference:

Large-molecular weight hyaluronic acid (molecular weight range: 1 800 000 ~ 2 200 000 Dalton)

Small-molecular weight hyaluronic acid (molecular weight range: 400 000 ~ 1 000 000 000 Dalton)

One hyaluronic acid molecule can lock up water more than 6000 times of its own weight

A research has shown that OJESH hyaluronic acid molecules can lock up water more than 6,000 times its own weight. This small molecular-weight hyaluronic acid from Germany has adopted a number of cutting-edge technologies that obtained German patents. The first micromolecular technology of biodegradation extraction and HTN™ patented extraction technology are currently at the international leading level in the research and development of hyaluronic acid. Here are some examples:

Patented technology: The pioneering technology of biodegradation extraction of micro-molecules

Extraction of micro-molecules through biodegradation utilizes glucose as a carbon-sourced fermentation broth. Grain is fermented in the culture medium for 48 hours, after which filtration is used to remove mycelium and impurities. Afterwards, alcohol precipitation and other purification operations are used to obtain high purity hyaluronic acid. OJESH's patented technique of biodegradation of micromolecules greatly improves the integrity of hyaluronic acid, allowing the structure of molecules that are automatically melted to stay in the skin for a long time.

Patent certificate of OJESH

Patented technology: HTN™ patented extraction technology

The technology was developed exclusively by Dr Wolfgang Schatton (the academic advisor of OJESH's brand) and his team. With HTN™ extraction technology, the essential active ingredients can penetrate into the skin several times faster than normal within the same period of time, with high efficiency and durability. After entering the dermis, they can quickly activate the growth of cells, replenish skin nutrition and promote skin metabolism.

Patented ingredients: Alpine edelweiss

Alpine Edelweiss grow in high mountains ranging from 1, 700 to 4, 500 meters. Intense stimulation and extreme temperature changes make it rich in natural chlorogenic acid and highly capable in self- repairing. It has significant effects on regeneration and activation of damaged basal cells, scavenging free radicals, and relieving and anti-inflammatory. The ingredient is currently patented in Germany.

Using technology to restore authentic beauty

Originated from Germany, OJESH adopts excellent patented technologies, and has established a distribution system in Europe, China, the United States, Japan, South Korea, Australia, United Arab emirates, Canada, southeast Asia and other countries and regions. OJESH's small molecule hyaluronic acid is convenient to use, and the effect is seen and proven. In just a few years, it has gained worldwide consumers' recognition.

Inpired by nature and powered by science, OJESH restores the most natural beauty of women. Through independent research and development, exploration and breakthrough, OJESH enables more people to enjoy the new experience brought by science and technology. This is a precious gift that technology has given to contemporary women and deserves to be given to all.

OJESH headquarters, Shenzhen, China

Contact:

Company name: Germany Jassen Group
Contact person: Mr. CHEN
Email address: service@ojesh.com
www.ojesh.de

SOURCE: Germany Jassen Group

ReleaseID: 571039

NEW YORK, NY / ACCESSWIRE / December 21, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or the "Company") (NASDAQ:ALLK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Allakos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On December 18, 2019, Seligman Research ("Seligman") published a report characterizing Allakos as "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." Among a litany of other issues, the Seligman report accused Allakos of having "buried the results for the two AK001 studies it conducted, but our research indicates a debacle"; having "a checkered history of conducting small, low-credibility trials, marked by a striking level of what we consider to be discrepancies, omissions, cherry-picking, and other red flags"; and engaging in "[f]lagrant nepotism in key clinical roles".

On this news, Allakos's stock price fell $13.25 per share, or 10%, to close at $119.28 on December 18, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 571006

NEW YORK, NY / ACCESSWIRE / December 21, 2019 / Financial technology (Fintech) used to describe new technology that seeks to improve and automate the delivery and use of financial services. A new FinTech knowledge and curriculum system has been announced by the Certified FinTech Analyst Institute recently.

The Certified FinTech Analyst (CFTA) Institute was founded by professional financial industry alumni from Washington and Webster Universities. Training FinTech professionals in artificial intelligence generation is the aim of this organization. CFTA officially launched a global certification system in June 2019. CFTA holder indicates those who have mastered FinTech with business/financial analyst identity.

Eligibility of Certified FinTech Analyst (CFTA)

The CFTA Institute operates globally and promotes financial specialists to obtain FinTech skills.

To register for the CFTA, a candidate must:

Have a financial background with a bachelor's degree, or be in the final year of completing a bachelor's degree
Have 24 years of full-time work experience in the financial industry or have passed CFTA or FRM LEVEL I exam
Have an international travel passport or ID number in specific countries
Must complete CFTA courses

Candidates must also pass all three levels of the CFTA exam. The CFTA Institute holds an exam in each level twice a year, in June and December. All three level exams are online and will be held in English and local languages.

CFTA Curriculum & Exam

CFTA exam & courses involve all the necessary skills for a financial analyst who is under this innovative generation, including computer programming (python), data processing and AI application in the financial area.

Level I exam: contains Python Programming, Database Technology and Application, Statistics in Python Application, FinTech in Economics, Analysis and Programming in Financial Statements.

Level II exam: consists of Quantitative System Design, Application of FinTech in Company Financial, Application of FinTech in investment, 1st part.

Level III exam: consists of Data Analysis and Application, Application of FinTech in Investment, part two, Application of FinTech in Risk Management and FinTech Advanced Application (block-chain, machine writing, NLP etc.)

It aims to help financial employees in their daily jobs with technology, rather than training IT specialists. Once a candidate completes all three levels of exams, they will become a member of the CFTA Institute.

Benefits

Firstly Candidates' personal skills in the financial market, including market analysis, investment research, quantitative trading and risk management etc, could be improved by studying CFTA courses. CFTA holders will have wider range of choices when selecting jobs.

So far, there are no FinTech specialist training courses/certifications in the market except CFTA. This gives CFTA members the first-mover advantage in the FinTech training market.

Lastly, according to our research in the human resource market, FinTech specialists or employees who have FinTech skills are offered a more than fifty percent higher salary than traditional finance offers. A candidate who possesses IT skills also has an advantage when competing with other candidates in the job-seeking process.

Difficulties

Learning IT skills is time-consuming, so people tend to abandon it easily. The CFTA is not a path of transfer from just any other jobs to the financial industry, since a financial background is requested. Additionally, CFTA is not well-known, since FinTech is a relatively new area. Therefore, employers may not value this certification on candidates' resumes.

Activities

According to CFTA institute, the Level I online curriculum will be open to college students and available on the free open course platform, Mooc. Students who have a major in finance, accounting and management will be eligible to apply for this free curriculum.

Contact

Organization Name: Certified FinTech Analyst Institute
Contact person: Chris Ng
Email: support@cftainstitute.org

SOURCE: Certified FinTech Analyst Institute

ReleaseID: 571040